Table 3 Linear and multivariate analysis of relationship between post-bronchodilator FEV1 % predicted and sputum sputum neutrophil percentage at 1 year.
From: Sputum neutrophils as a biomarker in COPD: findings from the ECLIPSE study
| Â | Linear Regression | Â | Multiple Regression | ||||
|---|---|---|---|---|---|---|---|
Independent Variables in Model | Estimate(SE) | p-value | R-square | Â | Estimate(SE) | p-value | R-square |
Age | -0.198 (0.137) | 0.150 | 0.007 | Â | 0.008 (0.129) | 0.950 | 0.209 |
BMI | 0.335 (0.158) | 0.034 | 0.015 | Â | 0.430 (0.151) | 0.005 | Â |
Concomitant ICS use | 8.241 (2.070) | <0.001 | 0.051 | Â | 8.075 (1.960) | <0.001 | Â |
Current smoking status | 2.486 (1.823) | 0.174 | 0.006 | Â | 0.959 (1.780) | 0.590 | Â |
Pack years | -0.056 (0.032) | 0.082 | 0.010 | Â | -0.036 (0.030) | 0.230 | Â |
Gender | 7.052 (1.858) | <0.001 | 0.047 | Â | 7.588 (1.780) | <0.001 | Â |
Sputum neutrophil % | -0.316 (0.057) | <0.001 | 0.094 | Â | -0.272 (0.056) | <0.001 | Â |